e-learning | Ertugliflozin in type 2 diabetes and the other SGLT-2 inhibitors

20th September 2019 by Louise Hudman

e-learning | Ertugliflozin in type 2 diabetes and the other SGLT-2 inhibitors

This is a new guideline from NICE giving advice on ertugliflozin, published in April 2019. I am also doing a quick reminder about the other SGLT-2 inhibitors.

What is ertugliflozin?

It is another sodium-glucose co-transporter 2 (SGLT-2) inhibitor, like canagliflozin, dapagliflozin and empagliflozin.

It is thought to be as effective as the other SGLT-2 inhibitors, but it is cheaper.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

Related content

"I am a newly qualified sessional GP. I am thankful to you and your team for the splendid work you do for all of us. LocumDeck is the only platform that allows GPs to be in control and I am glad I have been a member of NASGP since my trainee days."

Dr Karthik Krishna

See the full list of features within our NASGP membership plans

Membership